Physician profile
Ilan Kedan
NPI 1689629057
$1,492.94
in general payments reported to CMS, 2019-2025
18 companies · $709 in 2025
The $709 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $48.00 · 2023: $29.66 · 2024: $581 · 2025: $709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,319.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $231.58 | 2024-2025 | Repatha, Repatha |
| Abbvie INC. | $164.89 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $142.12 | 2021-2024 | Evkeeza |
| Madrigal Pharmaceuticals | $129.30 | 2024-2025 | Rezdiffra, Resmetirom |
| Alnylam Pharmaceuticals INC. | $110.64 | 2024-2025 | Amvuttra |
| Novo Nordisk INC | $102.75 | 2024-2025 | Wegovy |
| Lilly USA, LLC | $101.87 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $97.33 | 2024-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.73 | 2024-2025 | Jardiance |
| Ge Healthcare | $77.66 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $53.23 | 2025 | |
| Pfizer INC. | $33.56 | 2025 | |
| Baxter Healthcare | $32.05 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Kiniksa Pharmaceuticals International, Plc | $29.73 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $28.57 | 2025 | Farxiga |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $26.98 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.85 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $21.10 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilan Kedan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.